Overview of Self-medication Among French Navy Personnel (AutoMMaN)

Overview and Determinants of Self-medication Among Personnel Deployed on French Navy Surface Ships

The goal of this cross-sectional descriptive observational study is to assess the extent of self-medication among the crews of surface ships at the Toulon naval base. This study could include healthy volunteers, or participants with well-controlled chronic pathologies enabling them to be fit for embarkation, who are currently being deployed for at least 4 weeks on a surface ship at the naval base.

Participants will tick and complete a questionnaire (between 15 and 30 minutes) after 4 consecutive weeks on the ship.

Study Overview

• Status: Not yet recruiting
• Conditions: Self Medication
• Intervention / Treatment: Other: Questionnaire

• Study Type: Observational
• Enrollment (Estimated): 800

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

• Sampling Method: Non-Probability Sample

Study Population

healthy volunteers, or participants with well-controlled chronic pathologies enabling them to be fit for embarkation, military personnel currently deployed for at least 4 weeks on a naval base surface ship

Description

Inclusion Criteria:

• French military personnel;
• age > 18;
• embarked on a French navy vessel from the naval base;
• for a minimum 4-week mission;
• covered by social security.

Exclusion Criteria:

• Refusal to participate,
• Legionnaire
• Military Health Services member

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
percentage of patients who have self-medication	Percentage of patients who have self-medicated at least once since the start of their current mission, among respondents working on surface ships at the naval base on missions lasting more than 4 weeks (excluding malaria prophylaxis, contraception and treatment of a chronic pathology prescribed by a doctor)	up to 4 weeks

Collaborators and Investigators

• Sponsor: Direction Centrale du Service de Santé des Armées

Study record dates

Study Major Dates

• Study Start (Estimated): April 1, 2024
• Primary Completion (Estimated): March 1, 2026
• Study Completion (Estimated): April 1, 2026

Study Registration Dates

• First Submitted: March 21, 2024
• First Submitted That Met QC Criteria: March 28, 2024
• First Posted (Actual): March 29, 2024

Study Record Updates

• Last Update Posted (Actual): March 29, 2024
• Last Update Submitted That Met QC Criteria: March 28, 2024
• Last Verified: March 1, 2024

More Information

Terms related to this study

• Other Study ID Numbers: 2023PPRC04; 2023-A01763-42 (Other Identifier: IDRCB)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No